Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from commissioning to early utilization. With growing customer volume, Burcon is positioned to improve fixed-cost absorption at its Galesburg facility. The company completed commissioning and launched commercial production across Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein in fiscal year 2026.
Revenue increased sequentially to $0.83 million in the fourth quarter of fiscal 2026 from $0.74 million in the third quarter. Management indicated that current-quarter sales are tracking toward approximately 50% sequential growth based on April and May activity. Burcon also set a new production record, with daily output roughly 60% above January to March levels. As volume builds, the margin opportunity is expected to come from better utilization, a steadier production cadence, and start-up costs moving out of the run-rate cost structure, rather than pricing alone.
Customer traction is broadening, with more than 30 purchasing customers and over 200 active projects across pea, canola, and fava applications. Funding supports the Galesburg scale-up, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million of calendar year 2026 sales. For more details, view the full announcement here.
